Australia's Mesoblast extends gain on FDA support for proposed drug licence application

Mesoblast

27/03/2024 24:31

** Drug developer Mesoblast  MSB.AX  extends gain, rising as
much as 17.7% to A$0.565 - highest since Aug. 1, 2023
    ** MSB surged 45.5% on Tuesday after the U.S. FDA informed
co that clinical data from its Phase 3 study was sufficient to
support submission of proposed Biologics Licence Application
(BLA) for remestemcel-L 
    ** Co is developing remestemcel-L for inflammatory diseases
in children and adults including steroid refractory acute graft
versus host disease
    ** MSB top gainer on the ASX All Ordinaries index  .AORD 
    ** More than 29.3 mln shares change hands, nearly four times
the 30-day avg of 7.6 mln shares
    ** As of last close, stock up 54.8% this year

 (Reporting by Himanshi Akhand in Bengaluru)
 ((Himanshi.Akhand@thomsonreuters.com;))